Thursday, July 9, 2026

pharma · Social Anxiety Disorder · Drug Drug Interaction · VTGN

Vistagen Therapeutics

Vesigen Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker VTGN. Primary therapeutic focus areas include Social Anxiety Disorder, Drug Drug Interaction, Major Depressive

Cambridge, USA HQ
7 Employees
Public company Type
VTGN · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Employees
7
Programs
10
Drugs
3
Patents
6

Quick answer

Vesigen Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker VTGN. Primary therapeutic focus areas include Social Anxiety Disorder, Drug Drug Interaction, Major Depressive Disorder, Parkinson Disease, Social Anxiety Disorder (SAD). NovaPharmaNews links 10 clinical program(s), 0 drug profile(s), and 6 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (5), phase 3 (4), phase 1 (1).

Company snapshot

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (C

  • 10 active pipeline program(s) linked via ClinicalTrials.gov.
  • 6 US patent(s) indexed to this assignee profile.
  • 10 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Vistagen Therapeutics. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Vistagen Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 11 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Vistagen Therapeutics.

  1. Clinical update

    Placebo — Phase 2

  2. Clinical update

    PH94B Nasal Spray — Phase 3

  3. Clinical update

    Fasedienol Nasal Spray — Phase 3

  4. Clinical update

    Fasedienol Nasal Spray — Phase 3

  5. Clinical update

    Fasedienol Nasal Spray - Placebo Nasal Spray — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Vistagen Therapeutics?

    Vesigen Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker VTGN. Primary therapeutic focus areas include Social Anxiety Disorder, Drug Drug Interaction, Major Depressive Disorder, Parkinson Disease, Social Anxiety Disorder (SAD).

  • Is Vistagen Therapeutics publicly traded?

    Yes. Vistagen Therapeutics is listed with ticker VTGN on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Vistagen Therapeutics develop or market?

    We link 3 drug profile(s) where Vistagen Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/vistagen-therapeutics#company-drugs.

  • What are the latest developments for Vistagen Therapeutics?

    In the last 12 months our linked public records show 10 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Vistagen Therapeutics focus on?

    Vistagen Therapeutics focuses on Social Anxiety Disorder, Drug Drug Interaction, Major Depressive Disorder based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
14
Neurology
2